Zacks Investment Research upgraded shares of Enzymotec Ltd. (NASDAQ:ENZY) from a sell rating to a hold rating in a report published on Tuesday morning.

According to Zacks, “Enzymotec, Ltd. provides specialty lipid-based products and solutions. The Company develops, manufactures and markets bio-functional lipid ingredients as well as final products. It serves pharmaceuticals and nutrition industries worldwide. Enzymotec, Ltd. is based in Migdal HaEmeq, Israel. “

Separately, Jefferies Group reissued a hold rating on shares of Enzymotec in a research note on Thursday, August 4th.

Enzymotec (NASDAQ:ENZY) remained flat at $7.10 during midday trading on Tuesday. The company’s 50-day moving average price is $7.28 and its 200 day moving average price is $8.12. Enzymotec has a 12 month low of $6.60 and a 12 month high of $10.32. The company has a market cap of $161.30 million, a price-to-earnings ratio of 37.37 and a beta of 1.27.

Enzymotec (NASDAQ:ENZY) last issued its quarterly earnings data on Tuesday, August 9th. The company reported $0.04 EPS for the quarter, missing the Zacks’ consensus estimate of $0.08 by $0.04. The business earned $15 million during the quarter, compared to analyst estimates of $14.90 million. Enzymotec had a net margin of 8.37% and a return on equity of 3.12%. Enzymotec’s revenue was down 12.7% on a year-over-year basis. During the same period in the previous year, the company posted $0.11 earnings per share. Equities analysts forecast that Enzymotec will post $0.27 EPS for the current year.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Gagnon Securities LLC acquired a new position in Enzymotec during the second quarter valued at approximately $2,022,000. Gagnon Advisors LLC acquired a new position in Enzymotec during the second quarter valued at approximately $1,590,000. Laurion Capital Management LP acquired a new position in Enzymotec during the second quarter valued at approximately $1,572,000. Janus Capital Management LLC raised its position in Enzymotec by 79.3% in the second quarter. Janus Capital Management LLC now owns 248,485 shares of the company’s stock valued at $2,077,000 after buying an additional 109,933 shares during the last quarter. Finally, Acadian Asset Management LLC raised its position in Enzymotec by 47.2% in the second quarter. Acadian Asset Management LLC now owns 248,317 shares of the company’s stock valued at $2,076,000 after buying an additional 79,579 shares during the last quarter. Hedge funds and other institutional investors own 36.20% of the company’s stock.

About Enzymotec

Enzymotec Ltd. is a nutritional ingredients and medical foods company. The Company’s technologies, research expertise and clinical validation process enables it to develop solutions across a range of products. The Company operates in two segments: Nutrition segment and VAYA Pharma segment. Both of the Company’s segments offer a range of products that leverage its lipid-related offerings.

5 Day Chart for NASDAQ:ENZY

Receive News & Stock Ratings for Enzymotec Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzymotec Ltd. and related stocks with our FREE daily email newsletter.